Epithelial ovarian cancer is the leading cause of death from gynecologic cancer and the fifth most common cause of cancer mortality in women in the United States. Fewer than 40% of women with ovarian cancer are cured, and 70% of patients present with advanced disease; because of the location of the ovaries, ovarian cancer has been difficult to diagnose at earlier stages. Epidemiologic studies have identified risk factors, including family history. The NCCN guidelines discuss epithelial ovarian cancer as well as less common ovarian histopathologies, including germ cell neoplasms, carcinosarcomas (malignant mixed Müllerian tumors of the ovary), and ovarian stromal tumors. For 2008, updates include the addition of platinum-based combination therapy as a possible treatment modality for recurrence and a listing of preferred agents for acceptable recurrence modalities. New information was also added to the section on clinical presentation.
For the most recent version of the guidelines, please visit NCCN.org
If the inline PDF is not rendering correctly, you can download the PDF file here.
The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is committed to accelerating the fight against cancer through advances in prevention, detection, treatment, and research.Siteman offers more than 350 Washington University physicians and investigators who treat over 7,000 newly diagnosed patients each year and hold nearly $140 million in annual research and training grants. In addition to its main campus, Siteman has 2 network locations in the St. Louis area. Siteman physicians also collaborate with community hospitals and providers throughout the region.In recent years, Siteman's research efforts have expanded in several areas. In collaboration with Washington University's world-renowned Genome Sequencing Center, investigators are exploring translational cancer genomics. Faculty recruitments and the creation of an Institute for Public Health at Washington University have strengthened the prevention program. Other developments include the opening of a Center for Clinical Imaging Research, unique nationally for its integration in a patient-care setting, and advances in nanotechnology for cancer detection and treatment.Timothy Eberlein, MD (second photo on cover), has served as Siteman director since 1998. He also is chairman of the Department of Surgery at Washington University and surgeon-in-chief at Barnes-Jewish Hospital.